PTEN and osteosarcoma: Some of the drugs from our screen are already in clinical development for osteosarcoma (such as HDAC inhibitors), and an altered mTOR/PI3K/PTEN pathway was identified as a therapeutic target in 25% of tumors in a recently reported osteosarcoma genomic study [46].